Lilly cancer drug fails key trial, will no longer be prescribed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/4/2026

1. LULU
2. ZS
3. IOT
4. PATH
5. DOCU
6. ASAN
7. SPY
8. CIEN
9. GWRE
10. CPB

Go back to Lilly cancer drug fails key trial, will no longer be prescribed
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1149.76 -9.84 (0.85%)
Previous Close $1159.60    52 Week High $88.16 
Open $1150.61    52 Week Low $67.88 
Day High $1158.44    P/E 266.15 
Day Low $1147.76    EPS $4.32 
Volume 155,066